诺华公司宣布对其持有的印度子公司诺华印度有限公司 70.68% 的股权进行战略审查。 Novartis AG announces a strategic review of its 70.68% shareholding in Indian subsidiary, Novartis India Limited.
瑞士制药公司诺华公司宣布对其印度子公司诺华印度有限公司进行战略审查。 Swiss pharmaceutical company Novartis AG has announced a strategic review of its Indian subsidiary, Novartis India Limited. 此次审查将包括评估该公司在诺华印度公司70.68%的股权。 The review will include an assessment of the company's 70.68% shareholding in Novartis India. 不过，此次审查不会影响诺华医疗保健私人有限公司，该公司包括位于海得拉巴的诺华企业中心以及在该国 300 多个地点进行临床试验的研发团队。 However, the review will not affect Novartis Healthcare Private Limited, which includes the Novartis Corporate Center in Hyderabad and R&D teams conducting clinical trials at over 300 locations in the country. 无法保证战略审查将于 2024 年完成或促成任何交易。 There is no guarantee that the strategic review will be completed in 2024 or result in any transaction.